Key result
Adding rhBNP to levosimendan linked to ~16-point higher response rate in refractory heart failure.
Why the study?
The short-term clinical outcomes of adding recombinant human brain natriuretic peptide (rhBNP) to levosimendan in patients with refractory heart failure required evaluation.
Does adding recombinant human brain natriuretic peptide (rhBNP) to levosimendan improve short-term clinical efficacy, cardiac function indices, and vascular endothelial function in patients with refractory heart failure?
Cohort (n=100)
No
Does adding recombinant human brain natriuretic peptide (rhBNP) to levosimendan improve short-term clinical efficacy, cardiac function indices, and vascular endothelial function in patients with refractory heart failure?
Absolute Event Rate: 90% vs 74%
p-value: p=0.037
In patients with refractory heart failure, adding recombinant human brain natriuretic peptide to levosimendan was associated with greater short-term improvements in echocardiographic cardiac function, endothelial function markers, and clinical response rate compared with levosimendan alone, without a significant increase in adverse events.
rhBNP addition to levosimendan was associated with higher short-term response in refractory HF; leaves open confirmation in randomized trials before practice change.
To evaluate the short-term clinical outcomes of recombinant human brain natriuretic peptide (rhBNP) added to levosimendan in patients with refractory heart failure. This single-center retrospective cohort study included 100 patients with refractory heart failure who were hospitalized between January 2022 and June 2024. Patients were assigned according to the actual treatment regimen to either the combination group (levosimendan plus rhBNP) or the control group (levosimendan alone), with 50 patients in each group. Changes in cardiac function indices—left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO), and cardiac index (CI)—and endothelial function markers—nitric oxide (NO) and endothelin-1 (ET-1)—were compared between groups before and after treatment. Adverse events were recorded and analyzed. Baseline characteristics were comparable between the two groups. After treatment, the overall response rate was 90.00% in the combination group, significantly higher than 74.00% in the control group ( P = 0.037). LVEF, SV, CO, and CI increased significantly from baseline in both groups, with greater improvements observed in the combination group (all P < 0.05). The increase in NO and the decrease in ET-1 were also more pronounced in the combination group than in the control group (both P < 0.05). The incidence of adverse events did not differ significantly between groups ( P > 0.05). In patients with refractory heart failure, rhBNP combined with levosimendan was associated with greater short-term improvements in cardiac function, vascular endothelial function, and overall treatment response than levosimendan alone, without a significant increase in observed adverse events. Further prospective studies with larger sample sizes and longer follow-up are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
张竹轩 et al. (2026) conducted a cohort in Refractory heart failure (n=100). Recombinant human brain natriuretic peptide (rhBNP) plus levosimendan vs. Levosimendan alone was evaluated on Overall clinical response rate (improvement of ≥1 NYHA functional class or partial/marked symptom relief) (p=0.037). Adding rhBNP to levosimendan increased the short-term overall response rate compared to levosimendan alone (90.00% vs 74.00%, P = 0.037) in patients with refractory heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: